Physicians' Academy for Cardiovascular Education

ACC 2020

PACE-CME.org reports the virtual American College of Cardiology (ACC) Scientific Sessions 2020

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI

3' education - Apr. 7, 2020 - Prof. George Dangas, MD, PhD - ACC 2020

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

Higher rate of smoking cessation with e-cigarettes compared to counseling

3' education - Apr. 1, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events

3' education - Mar. 29, 2020 - Dr. Marc P. Bonaca, MD - ACC 2020

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence

10' education - Mar. 29, 2020 - Prof. Menno Huisman - ACC 2020

Risk of aorta stenosis events reduced by PCSK9i

News - Apr. 23, 2020

ACC 2020 This post-hoc analysis showed an association between increased Lp(a) and increased risk of aortic stenosis events. Evolocumab reduced risk of aorta stenosis after 1-year treatment.

PCSK9i treatment of dyslipidemic people with HIV reduces LDL-c and is safe

News - Apr. 21, 2020

ACC 2020 This trial showed that evolocumab treatment of dyslipidemic people living with HIV reduced LDL-c and other atherogenic lipids and lipoproteins and was well tolerated and safe.

PCSK9 inhibitor reduces VTE risk, especially in patients with high genetic risk

News - Apr. 21, 2020

ACC 2020 This analysis showed that a genetic risk score predicts VTE risk in patients with cardiometabolic disease and that evolocumab reduces the risk for VTE in patients in the top 1/3 of genetic risk.

Consistent treatment benefit of SGLT2i in HFrEF patients, regardless of background therapy

News - Apr. 16, 2020

ACC 2020 This post-hoc analysis of the DAPA-HF trial showed a consistent treatment benefit of dapagliflozin in HFrEF patients compared with placebo, regardless of background therapy.

No benefit of DAPT in addition to NOAC in symptomatic PAD patients undergoing revascularization

News - Apr. 9, 2020

ACC 2020 This subgroup analysis of the VOYAGER PAD trial demonstrated that addition of clopidogrel to rivaroxaban and aspirin has no added benefit in PAD patients undergoing revascularization, but may increase ISTH major bleeding.

P2Y12i monotherapy reduces net adverse clinical events in ACS patients undergoing PCI with DES

News - Apr. 9, 2020

ACC 2020 Ticagrelor monotherapy after 3-months DAPT reduces net adverse clinical events compared with continued DAPT in ACS patients who underwent PCI with drug-eluting stents (DES).

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD
Dirk Blom discusses the design and outcomes in the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

SGLT2i reduces first and recurrent events in patients with HFrEF

News - Apr. 9, 2020

ACC 2020 This pre-specified secondary analysis of the DAPA-HF trial showed that dapagliflozin reduces the risk of first and recurrent HF hospitalizations compared with placebo.

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD
Jonathan Cunningham discusses three findings from subanalyses of the PARAGON-HF trial in HFpEF patients.

ACC 2020 Jonathan Cunningham shares three major findings from a subanalysis of the PARAGON-HF trial in HFpEF patients.

ARNI treatment reduces NT-proBNP levels in HFpEF patients

News - Apr. 8, 2020

ACC 2020 A subanalysis of the PARAGON-HF trial demonstrated that treatment with the ARNI sacubitril/valsartan reduced NT-proBNP levels with 19% compared to valsartan alone in HFpEF.

Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI

3' education - Apr. 7, 2020 - Prof. George Dangas, MD, PhD - ACC 2020
George Dangas discusses the safety and efficacy results of the TWILIGHT-COMPLEX post-hoc study and compares the results with those of the overall TWILIGHT trial.

ACC 2020 George Dangas discusses the safety and efficacy results of the TWILIGHT-COMPLEX post-hoc study and compares the results with those of the overall TWILIGHT trial.

e-Cigarettes, with or without nicotine, increase smoking abstinence

News - Apr. 7, 2020

ACC 2020 This trial demonstrated that smoking e-cigarettes plus counseling for 12 weeks increased smoking abstinence and decreased daily cigarette use in participants of the general population compared to counseling alone.

ACC 2020